Abstract 1444P
Background
In the United States, uniquely American risk factors have led to a rise in the incidence of esophageal adenocarcinoma. In contrast, Asians have generally shown a predominance of esophageal squamous cell carcinoma (SCC), and this has held among Asian-Americans. However, limited investigation of esophageal cancer within Asian-Americans has been conducted in recent years.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Incidence Database was queried for patients from 2004-2020 classified as Asian/Pacific Islander and diagnosed with esophageal adenocarcinoma or squamous cell carcinoma. Descriptive statistics and multivariate models were utilized to compare incidence, cancer characteristics, treatment details, and survival in patients with esophageal adenocarcinoma and SCC.
Results
During this time, 2103 (73.71%) Asian-Americans presented with esophageal SCC compared to 750 (26.29%) with adenocarcinoma. Patients with SCC were diagnosed at a significantly older age (68.09 vs 66.10, p=<0.0001) and had a larger distribution of females (28.72% vs 15.20%, p<0.0001) than those with adenocarcinoma. The distribution of tumor stage was significantly different across these two groups (p<0.0001), with 292 (38.93%) adenocarcinoma patients diagnosed at stage IV compared to 546 (25.96%) patients with SCC. Cox regression analysis revealed that SCC was independently associated with worse survival (Hazard Ratio 1.115 (1.08-1.233)) compared to esophageal adenocarcinoma. Table: 1444P
Histological subtype | p-value | ||
Squamous cell carcinoma (N = 2103), N (%) | Adenocarcinoma (N = 750), N (%) | ||
Age, mean (years) | 68.09 | 66.10 | <0.0001 |
Sex | <0.0001 | ||
Female | 604 (28.72) | 114 (15.20) | |
Male | 1499 (71.28) | 636 (84.80) | |
Derived stage | <0.0001 | ||
I | 196 (9.32) | 72 (9.60) | |
II | 379 (18.02) | 97 (12.93) | |
III | 547 (26.01) | 166 (22.13) | |
IV | 546 (25.96) | 292 (38.93) | |
Unknown | 435 (20.68) | 123 (16.40) | |
Location of tumor | <0.0001 | ||
Upper third | 276 (13.12) | 11 (1.47) | |
Middle third | 692 (32.91) | 43 (5.73) | |
Lower third | 547 (26.01) | 566 (75.47) | |
Unclear/NOS | 588 (27.96) | 130 (17.33) | |
Cause of death | <0.0001 | ||
Alive | 452 (21.49) | 177 (23.6) | |
Esophageal cancer | 1300 (61.82) | 411 (54.8) | |
Other cause of death | 351 (16.69) | 162 (21.6) |
Conclusions
SCC remains the predominant histological subtype of esophageal cancer within Asian-Americans. Several factors may contribute to this, including BMI, immigration history, and retained cultural practices. However, adenocarcinoma should not be missed in this cohort. The later stage diagnosis of adenocarcinoma suggests that methods to improve early detection are necessary, and poorer survival of the SCC cohort indicates an opportunity to improve treatment paradigms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1515P - Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Presenter: Ryoji Takada
Session: Poster session 18
Resources:
Abstract
1516P - Lung-only metastatic PDAC: Another disease?
Presenter: Léa Mercier
Session: Poster session 18
Resources:
Abstract
1517P - Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Presenter: Giulia Orsi
Session: Poster session 18
Resources:
Abstract
1518P - Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Presenter: Leonoor Wismans
Session: Poster session 18
Resources:
Abstract
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Presenter: Makoto Ueno
Session: Poster session 18
Resources:
Abstract
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Presenter: Andreas Reichinger
Session: Poster session 18
Resources:
Abstract
1521P - Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Presenter: Hiroshi Imaoka
Session: Poster session 18
Resources:
Abstract
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
Resources:
Abstract
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18
Resources:
Abstract
1524P - Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
Presenter: Vincent Chung
Session: Poster session 18
Resources:
Abstract